J&J explores $20 billion sale of orthopedics unit: source

Core Viewpoint - Johnson & Johnson is preparing to potentially sell its orthopedics unit, DePuy Synthes, with a deal that could exceed $20 billion, targeting private equity firms as likely buyers [1][2]. Group 1: Company Strategy - J&J announced plans to separate its orthopedics unit into a standalone company within 18 to 24 months, marking its second major spinoff in two years to focus on higher-growth healthcare segments [2]. - The company is currently assembling documents and financials for DePuy Synthes in anticipation of meetings with potential buyers in the coming weeks [2]. Group 2: Financial Performance - J&J's orthopedics unit generated $9.3 billion in sales in 2025, producing products such as hip, knee, and shoulder implants, as well as surgical instruments [3]. Group 3: Legal Issues - The company has faced thousands of lawsuits related to hip replacement devices from the orthopedics unit, with 128 claims remaining unresolved out of nearly 10,600 in nationwide litigation concerning alleged design defects in DePuy's ASR hip replacement system [3][4]. Group 4: Separation Process - The CFO of J&J indicated that the company is exploring multiple paths for the separation, primarily focusing on a tax-free spinoff, while remaining open to other options [4]. - The separation process is already underway, with no significant updates expected until mid-2026 [4].